Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): An Eastern Cooperative Oncology Group Study
| Autor: | Gordon W. Dewald, Jane L. Liesveld, William R. Friedenberg, Elisabeth Paietta, Mary S. Young, Hussain T. Saba, Kenneth B. Miller, Wolfgang Hiddemann, Jacob M. Rowe, John M. Bennett, Robert D. Marsh, F. Ann Hayes, Hillard M. Lazarus |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Oncology
Chemotherapy education.field_of_study medicine.medical_specialty Mitoxantrone medicine.drug_class business.industry Myelodysplastic syndromes medicine.medical_treatment Population Phases of clinical research Hematology medicine.disease Antimetabolite Regimen Internal medicine medicine Cytarabine education business medicine.drug |
| Zdroj: | American Journal of Hematology. 66:23-27 |
| ISSN: | 1096-8652 0361-8609 |
| Popis: | Rambam Medical Center, Haifa, IsraelA Phase II study of GM-CSF with intermediate-dose cytarabine and mitoxantrone wasconducted in patients with high-risk myelodysplastic syndrome. It was designed to evalu-ate if priming with growth factor could increase the efficiency of chemotherapy. In thisolder population only two of 10 patients achieved a bone marrow CR, including onepatient whose leukemic blasts had an “S” phase increase of 2.55× at 48 hr. Unexpectedhepatotoxicity was noted. This regimen cannot be recommended for this elderly popu-lation of patients. Am. J. Hematol. 66:23–27, 2001. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text